Burkitt lymphoma (BL) is a highly malignant non-Hodgkin's lymphoma that is closely
related to the abnormal expression of genes. Familial acute myelogenous leukemia
related factor (FAMLF; GenBank accession No. EF413001.1) is a novel
gene that was cloned by our research group, and miR-181b is located in the intron of
the FAMLF gene. To verify the role of miR-181b and
FAMLF in BL, RNAhybrid software was used to predict target site
of miR-181b on FAMLF and real-time quantitative PCR (RQ-PCR) was
used to detect expression of miR-181b and FAMLF in BL patients, Raji
cells and unaffected individuals. miR-181b was then transfected into Raji and CA46
cell lines and FAMLF expression was examined by RQ-PCR and western
blotting. Further, Raji cells viability and proliferation were detected by MTT and
clone formation, and Raji cell cycle and apoptosis were detected by flow cytometry.
The results showed that miR-181b can bind to bases 21–42 of the
FAMLF 5′ untranslated region (UTR), FAMLF was
highly expressed and miR-181b was lowly expressed in BL patients compared with
unaffected individuals. FAMLF expression was significantly and
inversely correlated to miR-181b expression, and miR-181b negatively regulated
FAMLF at posttranscriptional and translational levels. A
dual-luciferase reporter gene assay identified that the 5′ UTR of
FAMLF mRNA contained putative binding sites for miR-181b.
Down-regulation of FAMLF by miR-181b arrested cell cycle, inhibited
cell viability and proliferation in a BL cell line model. Our findings explain a new
mechanism of BL pathogenesis and may also have implications in the therapy of
FAMLF-overexpressing BL.